Difference between revisions of "Carmustine (BCNU)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "chemocare.com/chemotherapy/drug-info" to "chemocare.com/druginfo")
(44 intermediate revisions by 5 users not shown)
Line 1: Line 1:
 
==General information==
 
==General information==
−
Class/mechanism: Nitrosourea, alkylates DNA and RNA, inhibits several key enzymatic processes by carbamoylation of amino acids in proteins.<ref name="insert">[http://packageinserts.bms.com/pi/pi_bicnu.pdf Carmustine (Bicnu) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/carmustine.pdf Carmustine (Bicnu) package insert (locally hosted backup)]</ref>
+
Class/mechanism: Nitrosourea, alkylates DNA and RNA, inhibits several key enzymatic processes by carbamoylation of amino acids in proteins.<ref name="insert">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6cbb63c-e0b1-43ee-ad6f-408da0772079 Carmustine (BiCNU) package insert]</ref><ref>[[:File:Carmustine.pdf | Carmustine (BiCNU) package insert (locally hosted backup)]]</ref>
 
<br>Route: IV
 
<br>Route: IV
 
<br>Extravasation: [[vesicant]]/[[irritant]]
 
<br>Extravasation: [[vesicant]]/[[irritant]]
  
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>.
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
 +
 
 +
==Diseases for which it is established ''(work in progress)''==
 +
*[[Peripheral T-cell lymphoma]]
 +
 
 +
==Diseases for which it is used==
 +
*[[Anaplastic glioma]]
 +
*[[CNS lymphoma]]
 +
*[[Diffuse large B-cell lymphoma]]
 +
*[[Follicular lymphoma]]
 +
*[[Glioblastoma]]
 +
*[[HIV-associated lymphoma]]
 +
*[[Classical Hodgkin lymphoma]]
 +
*[[Mantle cell lymphoma]]
 +
 
 +
==Diseases for which is was used==
 +
*[[Breast cancer - historical|Breast cancer]]
 +
*[[Melanoma - historical|Melanoma]]
 +
*[[Multiple myeloma_-_historical|Multiple myeloma]]
  
 
==Patient drug information==
 
==Patient drug information==
−
*[http://www.uptodate.com/contents/carmustine-patient-drug-information Carmustine (Bicnu) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/carmustine-patient-drug-information Carmustine (Bicnu) patient drug information (UpToDate)]</ref>
+
*[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6cbb63c-e0b1-43ee-ad6f-408da0772079 Carmustine (BiCNU) package insert]<ref name="insert"></ref>
 +
*[https://chemocare.com/druginfo/carmustine.aspx Carmustine (BiCNU) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/carmustine.aspx Carmustine (BiCNU) patient drug information (Chemocare)]</ref>
 +
*[http://www.uptodate.com/contents/carmustine-patient-drug-information Carmustine (BiCNU) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/carmustine-patient-drug-information Carmustine (BiCNU) patient drug information (UpToDate)]</ref>
  
−
==Regimens==
+
==History of changes in FDA indication==
−
Standard format will be:
+
*1977-03-07: Initial FDA approval
−
<br><acronym (if any)> <generic drug1, generic drug2, generic drug3, etc.> (disease)
+
*2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in [[:Category:CNS cancers|brain tumors]]: glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. ''(No supporting studies are cited)''
 +
*2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy for [[multiple myeloma]] in combination with prednisone. ''(No supporting studies are cited)''
 +
*2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy for [[Classical Hodgkin lymphoma|Hodgkin’s Disease]] as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. ''(No supporting studies are cited)''
 +
*2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy for [[:Category:Non-Hodgkin lymphomas|Non-Hodgkin’s lymphomas]] as secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. ''(No supporting studies are cited)''
 +
 
 +
==History of changes in EMA indication==
 +
*1974-04-23: EURD
 +
==Also known as==
 +
*'''Generic names:''' BCNU, bischloroethylnitrosourea, carmustin
 +
*'''Brand names:''' Becenun, BiCNU, Carmubris, Leucerom, Nitrourean, Nitrumon
  
 
==References==
 
==References==
 
<references/>
 
<references/>
 +
 +
[[Category:Drugs]]
 +
[[Category:Intravenous medications]]
 +
[[Category:Irritant]]
 +
[[Category:Vesicant]]
 +
 +
[[Category:Nitrosoureas]]
 +
[[Category:Alkylating agents]]
 +
 +
[[Category:Anaplastic glioma medications]]
 +
[[Category:CNS lymphoma medications]]
 +
[[Category:Diffuse large B-cell lymphoma medications]]
 +
[[Category:Follicular lymphoma medications]]
 +
[[Category:Glioblastoma medications]]
 +
[[Category:HIV-associated lymphoma medications]]
 +
[[Category:Classical Hodgkin lymphoma medications]]
 +
[[Category:Mantle cell lymphoma medications]]
 +
[[Category:Peripheral T-cell lymphoma medications]]
 +
 +
[[Category:Breast cancer medications (historic)]]
 +
[[Category:Melanoma medications (historic)]]
 +
[[Category:Multiple myeloma medications (historic)]]
 +
 +
[[Category:FDA approved in 1977]]
 +
[[Category:EMA approved in 1974]]

Revision as of 23:36, 2 September 2023

General information

Class/mechanism: Nitrosourea, alkylates DNA and RNA, inhibits several key enzymatic processes by carbamoylation of amino acids in proteins.[1][2]
Route: IV
Extravasation: vesicant/irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is established (work in progress)

Diseases for which it is used

Diseases for which is was used

Patient drug information

History of changes in FDA indication

  • 1977-03-07: Initial FDA approval
  • 2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in brain tumors: glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. (No supporting studies are cited)
  • 2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy for multiple myeloma in combination with prednisone. (No supporting studies are cited)
  • 2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy for Hodgkin’s Disease as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. (No supporting studies are cited)
  • 2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy for Non-Hodgkin’s lymphomas as secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. (No supporting studies are cited)

History of changes in EMA indication

  • 1974-04-23: EURD

Also known as

  • Generic names: BCNU, bischloroethylnitrosourea, carmustin
  • Brand names: Becenun, BiCNU, Carmubris, Leucerom, Nitrourean, Nitrumon

References

  1. ↑ 1.0 1.1 1.2 Carmustine (BiCNU) package insert
  2. ↑ Carmustine (BiCNU) package insert (locally hosted backup)
  3. ↑ Carmustine (BiCNU) patient drug information (Chemocare)
  4. ↑ Carmustine (BiCNU) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Carmustine_(BCNU)&oldid=77171"